In early‐onset AD and late‐onset AD subjects, higher CSF Tau values at baseline predicted higher rates of subcortical atrophy and might be a relevant molecular biomarker that could indicate disease pathology and/or progression in AD, which was often accompanied by axonal degeneration.49, 50. The gene discussed is MAPT; the disease is Atrophy.